ArticleLIMS

Why LIMS Implementations Fail

Six patterns that play out repeatedly across genomics, molecular diagnostics, and clinical lab environments. The culprit is almost never the technology.

Read →
ArticleLab Strategy

Laboratory Technical Debt

High-throughput platforms sitting at 40% utilization. Leadership won’t approve expansion. The overhead per sample makes growth uneconomical. How technical debt accumulates—and the path out.

Read →
ArticleLab Strategy

End-to-End Workflow Strategy in Clinical Labs

How to right-size your E2E architecture for your stage of growth, find your rate-limiting steps before you buy anything, and reframe your lab as a profit center.

Read →
ArticleTCO

The True Cost of Molecular Diagnostics Adoption

The seven costs labs miss before they buy — and how to model true cost of adoption.

Read →
ArticleLab Strategy

When Compromise Becomes Infrastructure

Every lab accepts compromises that fade into the operational background. Years later, they’re not decisions anymore — they’re infrastructure. How growing labs name and quantify what they stopped seeing.

Read →
ArticleDeployment

The Deployment Decision

The cloud vs. on-prem analysis that produced clean answers from 2017–2023 no longer holds without revisiting. A structured framework for lab leadership re-evaluating deployment strategy with current inputs.

Read →
FrameworkLab Readiness

Lab Readiness Assessment

33-question interactive assessment across 10 domains. Know your gaps before you commit to a platform.

Open →
FrameworkLIMS

LIMS Evaluation Scorecard

Score and compare LIMS vendors across deployment, integration, no-code capability, custom code exposure, workflow fit, and post-go-live support — built from real RFP experience on both sides of the table.

Open →
FrameworkDeployment

Deployment Discovery Framework

24-question interactive framework across 8 factors. Produces a directional hypothesis — cloud, hybrid, or on-prem — for your leadership team to pressure-test. Not a verdict.

Open →
My Story

Every Link in the Chain

I started my career at the end of the genomics chain and ended it owning the whole thing. HelixWrks exists to build for the problems I spent a decade watching go unsolved.

Read →